Af­ter search­ing for buy­ers for its "un­der­per­form­ing" as­sets, Charles Riv­er Lab­o­ra­to­ries has se­cured two deals.

It will sell some of its Eu­ro­pean dis­cov­ery ser­vices to the da­ta and ser­vices com­pa­ny IQVIA, while its CD­MO and cell so­lu­tions busi­ness­es will go to the pri­vate eq­ui­ty firm GI Part­ners, it said in a Wednes­day re­lease.

Charles Riv­er’s stock CRL was up 2.45% on Wednes­day.

Last week, the com­pa­ny’s CEO Jim Fos­ter said Charles Riv­er was in dis­cus­sions with po­ten­tial buy­ers, af­ter an­nounc­ing its plans in No­vem­ber to di­vest “un­der­per­form­ing or non-core as­sets” that make up 7% of its to­tal rev­enue.

IQVIA is pay­ing $145 mil­lion, with the po­ten­tial for an ad­di­tion­al $10 mil­lion, and will take over five fa­cil­i­ties, in­clud­ing a drug dis­cov­ery site in Cam­bridge, UK and phar­ma­col­o­gy fa­cil­i­ties in Freiburg, Ger­many; Kuo­pio, Fin­land; Por­tishead, UK; and Lei­den, the Nether­lands.

Vi­a­tris said it's plan­ning to cut up to 10% of its glob­al work­force in an ef­fort to save up to $700 mil­lion a year.

In its fourth-quar­ter earn­ings re­port, the gener­ic drug­mak­er on Thurs­day al­so dis­closed a fire at one fac­to­ry in In­dia and sup­ply is­sues at an­oth­er.

Fol­low­ing a strate­gic re­view of its busi­ness, Vi­a­tris said it will make re­struc­tur­ing changes over the next three years to save be­tween $600 mil­lion to $700 mil­lion an­nu­al­ly. At the end of 2025, Vi­a­tris em­ployed 32,000 work­ers.

The work­force cuts will im­pact dif­fer­ent di­vi­sions across Vi­a­tris’ busi­ness, in­clud­ing its com­mer­cial ser­vices, R&D, med­ical af­fairs and reg­u­la­to­ry ac­tiv­i­ties. The com­pa­ny ex­pects to in­cur be­tween $700 mil­lion and $850 mil­lion in re­struc­tur­ing-re­lat­ed charges.

The Penn­syl­va­nia-based com­pa­ny's stock was down about 2.35% on Thurs­day.

Pres­i­dent Don­ald Trump lost one av­enue to im­pose tar­iffs, but he still has the au­thor­i­ty to place du­ties on phar­ma­ceu­ti­cal im­ports.

Near­ly a year af­ter Trump’s chaot­ic "Lib­er­a­tion Day" tar­iff roll­out, the US Supreme Court ruled on Fri­day that Trump doesn’t have the au­thor­i­ty to im­pose tar­iffs un­der the In­ter­na­tion­al Emer­gency Eco­nom­ic Pow­ers Act (IEEPA). Trump had re­lied on the IEEPA to place broad, rec­i­p­ro­cal tar­iffs on a list of coun­tries in­clud­ing Chi­na (34%) and the EU (15%).

But the rul­ing does­n't im­pact sec­tor-spe­cif­ic tar­iffs un­der Sec­tion 232 of the Trade Ex­pan­sion Act of 1962, such as those for steel and alu­minum. The De­part­ment of Com­merce has been con­sid­er­ing po­ten­tial phar­ma­ceu­ti­cal tar­iffs un­der Sec­tion 232.

Sec­tion 232 “bears lit­tle on the mean­ing of IEEPA,” ac­cord­ing to the Fri­day rul­ing.

Ab­b­Vie is in­vest­ing $380 mil­lion to build two new ac­tive phar­ma­ceu­ti­cal in­gre­di­ent fac­to­ries in Illi­nois as part of its $100 bil­lion pledge to the US.

The two fa­cil­i­ties will be lo­cat­ed at its North Chica­go cam­pus and will make APIs for the com­pa­ny's neu­ro­science and obe­si­ty drugs, ac­cord­ing to a Mon­day re­lease. Ab­b­Vie has one obe­si­ty drug in its pipeline, a Phase 1 long-act­ing amylin ana­log called AB­BV-295 (GUB014295), which it li­censed from Gubra last March.

Con­struc­tion will start in the spring, and the sites are ex­pect­ed to be op­er­a­tional in 2029. About 300 new jobs will be cre­at­ed.

Ab­b­Vie is in dis­cus­sions with “mul­ti­ple” US states about fu­ture man­u­fac­tur­ing in­vest­ments, with fur­ther an­nounce­ments ex­pect­ed to come this year, the com­pa­ny said in the re­lease.

Bio­Mar­in's pre­vi­ous CEO want­ed to of­fer mon­ey-back guar­an­tees to in­sur­ers for cov­er­ing its he­mo­phil­ia gene ther­a­py Roc­ta­vian. In­vestors in the com­pa­ny may wish that such a promise on per­for­mance could have al­so in­clud­ed them.

For all its block­buster hopes and high-pro­file sta­tus in the gene ther­a­py field, Roc­ta­vian's com­mer­cial saga has end­ed. Af­ter a few months of seek­ing to di­vest Roc­ta­vian, Bio­Marin said Mon­day it has failed to find "a qual­i­fied buy­er" for the gene ther­a­py and will vol­un­tar­i­ly with­draw it from the mar­ket.